Research tagged [immunology]

Immune Checkpoint Inhibitor Rechallenge After Grade 3 Myocarditis in Metastatic Melanoma: A Community Peer-Reviewed Clinical Consensus and Management Framework

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet they are associated with immune-related adverse events (irAEs), including potentially fatal myocarditis. Current guidelines universally recommend permanent discontinuation of ICIs following grade 3 or 4 myocarditis. This consensus paper addresses the critical clinical dilemma of managing progressive metastatic melanoma in a patient who achieved an excellent initial response to pembrolizumab but subsequently developed grade 3 myocarditis, which fully resolved. Utilizing a community peer-review platform involving two expert oncologists and 91 peer votes, a nuanced framework for considering ICI rechallenge was developed. The framework emphasizes stringent criteria, including complete resolution of myocarditis, lack of alternative effective therapies, and life-threatening cancer with prior ICI response, alongside comprehensive patient counseling and intensive cardio-oncology monitoring. Strategies discussed include switching to anti-CTLA4 monotherapy, reduced-dose anti-PD1 rechallenge, and the potential role of prophylactic abatacept or pre-rechallenge endomyocardial biopsy. While acknowledging the significant risks, including a reported 30-60% recurrence rate of myocarditis, the consensus highlights that in highly selected cases with limited alternatives, a carefully managed rechallenge may be considered under strict multidisciplinary oversight. This paper provides an evidence-informed approach to navigate this complex clinical scenario, balancing oncologic benefit with critical cardiac safety.